Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Engineering human IL-18 with increased bioactivity and bioavailability.

Bethany Swencki-Underwood1, Mark R Cunningham, George A Heavner

  • 1Centocor Inc., Biopharmaceutical Research, 145 King of Prussia Road, Radnor, PA 19087, USA. bswenck2@cntus.jnj.com

Cytokine
|June 6, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accurate quantification of anti-drug antibodies against each unique Fab of a bispecific antibody using an ECL bridging assay.

Bioanalysis·2026
Same author

A synthetic gut microbiota provides an understanding of the maintenance and functional impact of phage.

mBio·2025
Same author

Unique challenges required reassessment and alterations to critical reagents to rescue a neutralizing antibody assay.

Bioanalysis·2024
Same author

2023 White Paper on Recent Issues in Bioanalysis: ISR for ADA Assays, the Rise of dPCR vs qPCR, International Reference Standards for Vaccine Assays, Anti-AAV TAb Post-Dose Assessment, NanoString Validation, ELISpot as Gold Standard <u>(Part 3</u> - Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Biotherapeutics Immunogenicity & Risk Assessment; ADA/NAb Assay/Reporting Harmonization).

Bioanalysis·2024
Same author

2022 White Paper on Recent Issues in Bioanalysis: FDA Draft Guidance on Immunogenicity Information in Prescription Drug Labeling, LNP & Viral Vectors Therapeutics/Vaccines Immunogenicity, Prolongation Effect, ADA Affinity, Risk-based Approaches, NGS, qPCR, ddPCR Assays (<u>Part 3</u> - Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Immunogenicity & Risk Assessment of Biotherapeutics and Novel Modalities; NAb Assays Integrated Approach).

Bioanalysis·2023
Same author

Survey Outcome on Immunogenicity Risk Assessment Tools for Biotherapeutics: an Insight into Consensus on Methods, Application, and Utility in Drug Development.

The AAPS journal·2023
Same journal

The multifaceted role of acetamide derivative of chalcone: Anti-inflammatory action and impact on osteoclastogenesis, insights on NF-κB and MAPK pathway.

Cytokine·2026
Same journal

Icariin alleviates ovariectomy-induced osteoporosis by promoting M2 macrophage polarization and suppressing osteoclast activation.

Cytokine·2026
Same journal

Single-cell profiling of the immune landscape at the maternal-fetal interface in unexplained recurrent miscarriage.

Cytokine·2026
Same journal

EGFR as a context-dependent modulator of endothelial inflammation: A systematic review.

Cytokine·2026
Same journal

Harnessing the Power of IL-12: Revolutionizing Cancer Therapy with Combinatorial Strategies.

Cytokine·2026
Same journal

Corrigendum to "CCL17 and CCL19 are markers of disease progression in alveolar echinococcosis" [Cytokine 181 (2024) 156669].

Cytokine·2026
See all related articles

Interleukin-18 (IL-18) can enhance DNA vaccine immune responses. Researchers developed and tested IL-18 variants, finding one (V11I/T63A) with improved bioactivity and expression for potential use as a vaccine adjuvant.

Area of Science:

  • Immunology
  • Molecular Biology
  • Vaccinology

Background:

  • Cytokines, such as interleukin-18 (IL-18), can function as adjuvants in DNA vaccines, boosting immune responses to encoded antigens.
  • IL-18 has demonstrated adjuvant properties with specific DNA vaccine formulations.

Purpose of the Study:

  • To optimize interleukin-18 (IL-18) for enhanced efficacy as a DNA vaccine adjuvant.
  • To identify IL-18 variants with improved receptor binding and bioactivity through computational modeling and experimental validation.

Main Methods:

  • Developed a computational model for IL-18/IL-18 receptor (IL-18R) binding to predict beneficial IL-18 variants.
  • Engineered and expressed IL-18 variants linked to a secretion signal sequence in mammalian cells.
  • Assessed bioactivity of secreted IL-18 variants by measuring interferon gamma (IFNgamma) induction in peripheral blood mononuclear cells (PBMCs) and IL-18R binding via BIAcore analysis.

Related Experiment Videos

  • Evaluated inhibition of IL-18 variants by IL-18 binding protein (IL-18BP).

    • Main Results:

    • Secreted IL-18 variants exhibited bioactivity, inducing IFNgamma production in PBMCs and binding to IL-18R.
    • IL-18 variants were susceptible to inhibition by IL-18BP, as shown by neutralization assays.
    • One variant, V11I/T63A, demonstrated significantly enhanced bioactivity and improved expression in mammalian cells compared to native IL-18.

    Conclusions:

    • The engineered IL-18 variant V11I/T63A shows promise as a DNA vaccine adjuvant due to increased bioactivity and expression.
    • This optimized IL-18 variant could potentially lead to more effective DNA vaccine formulations.
    • Further research into this variant could advance the development of novel vaccine strategies.